Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1272
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 697–708 of 1,272 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 3 Interventional

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

NCT05812807
Status at this site: Recruiting
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Interventions
Pembrolizumab, Patient Observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Biological · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
828
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 600 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Active, not recruiting Not applicable Interventional

Abbott Medical - VERITAS Study

NCT06707688
Site status not listed — check the official record
View directory record Official record
Conditions
Atrial Fibrillation (AF), Stoke
Interventions
Amulet™ 2 Left Atrial Appendage (LAA) Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Recruiting Phase 3 Interventional

E-Mindfulness Approaches for Living After Breast Cancer

NCT06748222
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer, Depression
Interventions
Mindfulness (MAPs) Live Online, Mindfulness (MAPs) Digital App, Meditation Only Control Group
Behavioral
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 50 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
381
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 317 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

NCT07742735
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
Interventions
Apraglutide, Placebo
Drug
Lead sponsor
VectivBio AG
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Recruiting No phase listed Observational

Point-of-Care Ophthalmic Diagnostic Imaging of Retinopathy of Prematurity

NCT06612541
Status at this site: Recruiting
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP), ROP Examination
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
24 Weeks to 34 Weeks
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Active, not recruiting No phase listed Observational

Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies

NCT06486428
Site status not listed — check the official record
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Not listed
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
52
States / cities
Multiple Locations, Alabama • Multiple Locations, Alaska • Multiple Locations, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

NCT06162715
Site status not listed — check the official record
View directory record Official record
Conditions
Severe Obesity, Obesity, BMI Greater Than 30
Interventions
Tirzepatide, Standard of Care post-gastric bypass
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Recruiting Phase 1 Interventional

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

NCT06819228
Status at this site: Recruiting
View directory record Official record
Conditions
HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma
Interventions
Panitumumab IRDye 800
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Active, not recruiting Not applicable Interventional

Integrative Approaches for Cancer Survivorship (IACS3)

NCT06633926
Site status not listed — check the official record
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Nutrition Education, Lifestyle Counseling, Yoga, Marma therapy, Educational Intervention, Quality of Life Questionnaire Administration
Behavioral · Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
San Francisco, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Active, not recruiting Phase 3 Interventional

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636
Site status not listed — check the official record
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

NCT02893917
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma With Neuroendocrine Differentiation, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Cediranib, Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 31, 2026, 6:28 PM EDT
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

NCT06701669
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort B: paridiprubart, Cohort B: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 31, 2026, 6:28 PM EDT

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.